Speaker Biography

Leonard Mazur, Co-Founder, CEO and Chairman of the Board of Directors

Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable success in founding and building multiple healthcare companies and creating value and returns for investors throughout his five-decade career. Mr. Mazur was the co-founder and Chairman of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He was previously the co-founder and Vice Chairman of Akrimax Pharmaceuticals, LLC, which specialized in cardiovascular and general pharmaceutical products. From 2005 to 2012, Mr. Mazur co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC, a specialty pharmaceutical company producing prescription dermatological drugs. As founder and Chief Executive Officer of Genesis Pharmaceuticals, Inc., a dermatological products company that marketed its products through dermatologists’ offices and co-promoted products for major pharmaceutical companies, he successfully negotiated the company’s sale in 2003 to Pierre Fabre, a leading global pharmaceutical company. Mr. Mazur has extensive sales, marketing, and business development experience from previous tenures at Medicis Pharmaceutical Corporation, ICN Pharmaceuticals, Inc., Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.

Mr. Mazur was born in Ansbach, Germany, and emigrated with his family to the U.S. at an early age. Mr. Mazur served in the U.S. Marine Corps Reserve while studying at Temple University for his undergraduate degree. He earned his MBA from Temple University’s Fox School of Business in 1975.

Mr. Mazur is a recipient of the Ellis Island Medal of Honor presented annually to those who immigrated to the United States during the Ellis Island era and have shown an outstanding commitment to serving the United States either professionally, culturally, or civically.

About Citius Pharmaceuticals

Unlocking Potential. Faster.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products.

Our team’s extensive experience in the pharmaceutical industry allows us to identify compelling opportunities and develop assets that have unique commercial advantages and differentiated upside potential. By deploying capital thoughtfully, we believe our activities will provide patients and caregivers with improved treatment options and deliver long-term sustainable value to shareholders.

Our diversified pipeline of therapies targeting unmet medical needs includes three potential first-and-only prescription treatments in their indications, and a next-generation single-donor, allogeneic, clonal and scalable stem cell therapy program.